Pilot Study to Assess Centralizing Biological Samples for Molecular Characterization in Patients with Oncohematologic Diseases Referred to CROP Centers

What this Trial Is About

Researchers are evaluating the feasibility of centralizing and molecularly characterizing biological samples from patients with suspected oncologic, hematologic, or onco-immunologic diseases at onset or relapse. This study aims to improve data collection and management at the IRCCS AOU Meyer Oncohematology Laboratories, supporting personalized disease assessment and targeted therapies for pediatric and young adult patients up to 30 years old. Participants suspected of having these diseases will have their biological samples collected and analyzed for molecular markers, including DNA, RNA, and circulating free DNA. Analyses involve techniques such as digital PCR, Sanger sequencing, targeted resequencing, and next-generation sequencing to detect mutations and gene fusions. This centralization process is intended to create a translational database that could be linked to a future biobank. During the study, researchers will monitor sample delivery times, labeling accuracy, suitability for RNA extraction, and the quality and quantity of extracted material. They will also track the production time of research reports and gather clinical data from patients. The study will last at least five years, focusing on enhancing regional infrastructure for timely and comprehensive clinical and biological data collection to benefit current and future patients.

Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology